廖星;戴泽琦;吴雪;罗辉;赵晖;张霄潇;贾露露;唐健元;
LIAO Xing;DAI Ze-qi;WU Xue;LUO Hui;ZHAO Hui;ZHANG Xiao-xiao;JIA Lu-lu;TANG Jian-yuan;Center for Evidence-based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences;China Center for Evidence-based Traditional Chinese Medicine;Institute for Tibetan Medicine,China Tibetology Research Center;China Association of Chinese Medicine;Beijing Children′s Hospital Affiliated to Capital Medical University;Hospital of Chengdu University of Traditional C

• 1:中国中医科学院中医临床基础医学研究所循证医学基础研究室
• 2:中国中医药循证医学中心
• 3:中国藏学研究中心藏医药研究所
• 4:中华中医药学会

摘要(Abstract)：

中成药临床综合评价是当前中医药评价领域内的一个重要方向，对中医药行业的发展有着积极推动作用。中成药临床综合评价体系的建立，有助于在证据和价值基础上对同类别不同中成药、不同剂型和规格中成药，以及不同生产厂家中成药的“临床综合价值”进行综合评估。建立科学合理的中成药综合评价指标体系是保证其发挥临床价值的重要前提。然而目前，尚未见到对中成药临床综合评价公认的系统论述以及可借鉴的方法学体系。由国际研究团队研发的证据与价值：对决策的影响(the evidence and value:impact on decision-making, EVIDEM)框架被用于评估医疗干预措施的综合价值。EVIDEM框架围绕证据与价值观，基于多准则决策分析(multi-criteria decision analysis, MCDA)模型和卫生技术评估(health technology assessment, HTA),为科学决策提供了方法学工具。该文在团队目前正在开展的EVIDEM实证研究基础上，提出基于EVIDEM框架的中成药临床综合评价主要包括4个环节、7个模块、10个步骤。通过该研究的应用探索，期望为未来中医药领域开展中成药临床综合评价提供方法借鉴和实践经验。
The clinical comprehensive evaluation of Chinese patent medicine is an important direction in the evaluation of traditional Chinese medicine(TCM), which positively promotes the development of TCM industry. The evaluation system of Chinese patent medicine is helpful to comprehensively evaluate the clinical value of different Chinese patent medicine in the same category, different dosage forms, and specifications, from different manufacturers on the basis of evidence and value. The establishment of a scientific and reasonable comprehensive evaluation index system for Chinese patent medicine is an important prerequisite to ensure clinical value. However, there has been neither a recognized systematic review on the clinical comprehensive evaluation of Chinese patent medicine nor a methodological system used for reference. The evidence and value: impact on decision-making(EVIDEM), developed by the international research team, is used to evaluate the comprehensive value of medical interventions. EVIDEM provides a methodological tool for scientific decision-making to evaluate evidence and value for health technologies on the basis of the multi-criteria decision analysis(MCDA) model and health technology assessment(HTA). Based on the ongoing EVIDEM research, the present study put forward that EVIDEM-based clinical comprehensive evaluation of Chinese patent medicine consisted of four aspects, seven modules, and ten steps, which is expected to references and practical experience for the follow-up comprehensive evaluation of Chinese patent medicine in the TCM field.

关键词(KeyWords)： 中成药;临床综合评价;卫生技术评估;多准则决策分析;EVIDEM框架;证据与价值
Chinese patent medicine;clinical comprehensive evaluation;health technology assessment(HTA);multi-criteria decision analysis(MCDA);evidence and value: impact on decision-making(EVIDEM);evidence and value

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目(82174239);; 中国中医科学院科技创新工程项目(CI2021A00701-3);中国中医科学院基本科研业务费优秀青年科技人才(创新类)培养专项(ZZ13-YQ-075);;中国中医科学院第十四批基本科研业务课题项目(Z0718,Z0724);; 中国中医药循证医学中心“业务研究室主任专项”(2020YJSZX-2)

作者(Authors): 廖星;戴泽琦;吴雪;罗辉;赵晖;张霄潇;贾露露;唐健元;
LIAO Xing;DAI Ze-qi;WU Xue;LUO Hui;ZHAO Hui;ZHANG Xiao-xiao;JIA Lu-lu;TANG Jian-yuan;Center for Evidence-based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences;China Center for Evidence-based Traditional Chinese Medicine;Institute for Tibetan Medicine,China Tibetology Research Center;China Association of Chinese Medicine;Beijing Children′s Hospital Affiliated to Capital Medical University;Hospital of Chengdu University of Traditional C

DOI: 10.19540/j.cnki.cjcmm.20220211.501

参考文献(References)：

• [1] 国家卫生健康委药物政策与基本药物制度司.国家卫生健康委关于开展药品使用监测和临床综合评价工作的通知.国卫药政函[2019]80号[EB/OL].(2019-04-09) [2022-01-18].http://www.nhc.gov.cn/yaozs/pqt/201904/31149bb1845e4c019 a04f30c0d69c2c9.shtml.
• [2] 国家卫生健康委药物政策与基本药物制度司.国家卫生健康委办公厅关于规范开展药品临床综合评价工作的通知.国卫办药政发[2021]16号[EB/OL].(2021-07-28) [2022-01-18].http://www.nhc.gov.cn/yaozs/s2908/202107/532e2080 0a47415d84adf3797b0f4869.shtml.
• [3] 国家卫生健康委卫生发展研究中心(国家药物和卫生技术综合评估中心).关于心血管病、抗肿瘤、儿童药品临床综合评价技术指南公开征求意见的公告[EB/OL].(2021-12-31) [2022-01-18].http://www.nhei.cn/nhei/znfb/202112/9e350 a54d2ea4 c3ab9a0237ee4eab9f0.shtml.
• [4] 石秀园，赵锐，李璠，等.构建我国药品临床综合评价工作机制的思考[J].中国药房，2020,31(23):2828.
• [5] 谢雁鸣，廖星，姜俊杰，等.中成药上市后安全性医院集中监测技术规范[J].中国中药杂志，2019,44(14):2896.
• [6] 方赛男，孙塑伦，郭宇博，等.中成药临床应用专家共识制订有关问题讨论[J].中国中药杂志，2018,43(24):4792.
• [7] 田金洲，张伯礼，高学敏，等.制定中成药治疗优势病种临床应用指南的指导意见[J].中国中西医结合杂志，2018,38(1):7.
• [8] 王亚锋，刘强，杜敏，等.中成药上市后临床评价的整体设计[J].世界中医药，2018,13(2):484.
• [9] 廖星，郭武栋，曹庄，等.应用卫生技术评估开展中成药临床综合评价[J].中国中药杂志，2020,45(16):3749.
• [10] O′ROURKE B,OORTWIJN W,SCHULLER T.The new definition of health technology assessment:a milestone in international collaboration[J].Int J Technol Assess Health Care,2020,36(3):187.
• [11] 郭武栋，李雪，陈金榆，等.药品多维度价值判断评估工具包模拟案例[J].中国卫生资源，2020,23(4):348.
• [12] 宋子扬，尉耘翠，聂晓璐，等.基于卫生技术评估联合多准则决策分析建立我国儿童用药临床综合评价方法[J].药物流行病学杂志，2019,28(10):681.
• [13] 中国药品综合评价指南项目组.中国药品综合评价指南参考大纲(第二版)[J].药品评价，2015,12(8):6.
• [14] KRISTIAN L,MARJUKKA M,MARCIAL V G,et al.The HTA core model:a novel method for producing and reporting health technology assessments[J].Int J Technol Assess Health,2009,25(Suppl S2):9.
• [15] GOETGHEBEUR M M,WAGNER M,KHOURY H,et al.Evidence and value:impact on decision making--the EVIDEM framework and potential applications[J].BMC Health Serv Res,2008,8:270.
• [16] MANN R D,RAWLINS M D,AUTY R M.Textbook of pharmaceutical medicine:current practice[M].London:the Parthenon Publishing Group,1993.
• [17] WALK S,CONE M.Benefit-risk assessment:summary report of a model for benefit-risk assessment of medicines based on multi-criteria decision analysis[R].Epsom,Surrey:CMR International Institute for Regulatory Science,2004.
• [18] WALK S,PHILLIPS L,CONE M.Benefit-risk assessment model for medicines:developing a structured approach to decision ma-king[R].Epsom,Surrey:CMR International Institute for Regulatory Science,2006.
• [19] MUSSEN F,SALEK S,WALKER S.A quantitative approach to benefit-risk assessment of medicines--part 1:the development of a new model using multi-criteria decision analysis[J].Pharma-coepidem Dr S,2007,16(Suppl 1):s16.
• [20] GOETGHEBEUR M M,CELLIER M S.Can reflective multicriteria be the new paradigm for healthcare decision-making?The EVIDEM journey[J].Cost Effect Resour A,2018,16(Suppl 1):s54.
• [21] TONY M,WAGNER M,KHOURY H,et al.Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA):field testing of the EVIDEM framework for coverage decisions by a public payer in Canada[J].BMC Health Serv Res,2011,11(1):329.
• [22] RADAELLI G,LETTIERI E,MASELLA C,et al.Implementation of EUnetHTA core model(R) in Lombardia:the VTS framework[J].Int J Technol Assess Health Care,2014,30(1):105.
• [23] 耿劲松，鲍海妮，余小兰，等.“证据与价值对决策的影响”框架在知证决策中应用的方法学[J].中国卫生资源，2020,23(4):342.
• [24] GOETGHEBEUR M M,WAGNER M,KHOURY H,et al.Brid-ging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA):applying the EVIDEM framework to medicines appraisal[J].Med Decis Making,2012,32(2):376.
• [25] MAYOR S.WHO priority list of medical devices for cancer ma-nagement[J].Lancet Oncol,2017,18(7):856.
• [26] 宋子扬，尉耘翠，聂晓璐，等.基于卫生技术评估联合多准则决策分析建立我国儿童用药临床综合评价方法[J].药物流行病学杂志，2019,28(10):681.
• [27] YU Y,JIA L,MENG Y,et al.Method development for clinical comprehensive evaluation of pediatric drugs based on multi-criteria decision analysis:application to inhaled corticosteroids for children with asthma[J].Pediatr Drugs,2018,20(2):195.
• [28] 耿劲松，陈晓炜，余小兰，等.基于EVIDEM的新技术医保报销循证决策框架探析[J].中国卫生政策研究，2018,11(4):50.
• [29] 戴泽琦，徐思敏，吴雪，等.EVIDEM框架介绍及其在卫生决策中的应用[J].中国实验方剂学杂志，2022,28(4):212.
• [30] MARSH K,IJZERMAN M,THOKALA P,et al.Multiple criteria decision analysis for health care decision making--emerging good practices:report 2 of the ISPOR MCDA emerging good practices task force[J].Value Health,2016,19(2):125.
• [31] THOKALA P,DEVLIN N,MARSH K,et al.Multiple criteria decision analysis for health care decision making--an introduction:report 1 of the ISPOR MCDA emerging good practices task force[J].Value Health,2016,19(1):1.
• [32] 徐菲，唐密，胡善联，等.多准则决策分析应用于卫生决策的假设基础与基本操作[J].中国卫生资源，2020,23(4):332.
• [33] ANGELIS A,LINCH M,MONTIBELLER G,et al.Multiple criteria decision analysis for HTA across four EU member states:pilo-ting the advance value framework [J].Soc Sci Med,2019,246:112595.
• [34] 熊玮仪，董铎.基于多准则决策分析模型的药品获益风险评价方法[J].中国药物警戒，2017,14(12):752.
• [35] European Medicines Agency.Benefit-risk methodology project.Workpackage 3 report:field tests[EB/OL].(2011-08-31) [2022-01-18].https://www.ema.europa.eu/en/documents/report/benefit-risk-methodology-project-work-package-3-report-field-tests_en.pdf.
• [36] MORENO-CALDERóN A,TONG T S,THOKALA P.Multi-criteria decision analysis software in healthcare priority setting:a systematic review[J].Pharmacoeconomics,2020,38(3):269.
• [37] 胡善联.多准则决策分析在卫生决策领域中的应用价值[J].中国卫生资源，2020,23(4):325.
• [38] HIGGINS J P T,THOMAS J,CHANDLER J,et al.Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021)[EB/OL].(2021-02-01) [2022-01-18].https://training.cochrane.org/handbook/current.
• [39] GUYATT G H,OXMAN A D,VIST G E,et al.GRADE:an emerging consensus on rating quality of evidence and strength of recommendations[J].Br Med J,2008,336(7650):924.
• [40] 嵇承栋，朱琳懿，万悦竹，等.国际卫生技术评估机构协作网卫生技术评估报告清单解读[J].中国循证医学杂志，2016,16(3):369.
• [41] 国家医疗保障局，国家中医药管理局.国家医疗保障局国家中医药管理局关于医保支持中医药传承创新发展的指导意见[EB/OL].(2020-12-30) [2022-01-18].http://yzs.satcm.gov.cn/zhengcewenjian/2021-12-30/23898.html.
• [42] 张虹，夏慧琳，高关心，等.欧洲卫生技术评估发展对我国的启示[J].中国医学装备，2019,16(6):182.
• [43] The USC Schaeffer Center for Health Policy & Economics and the Aspen Institute.Health technology assessment for the US.Healthcare system white paper[EB/OL].(2020-02-26) [2022-01-18].https://healthpolicy.usc.edu/research/health-technology-assessment-for-the-u-s-healthcare-system/.
• [44] 房良，王海银，程文迪，等.日本卫生技术评估机制建设研究与启示[J].卫生软科学，2019,33(5):9.